Moloxin Dosage/Direction for Use

Posology: The recommended dose for Moloxin is 400 mg once daily (1 film-coated tablet) for the previously mentioned indications and should not be exceeded. The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.
For complicated skin and skin structure infections, therapy should usually be initiated with intravenous formulation. When switching from intravenous to oral dosage administration, no dosage adjustment is necessary. Patients whose therapy is started with Moloxin I.V. may be switched to Moloxin Tablets when clinically indicated at the discretion of the physician.
Duration of administration: The duration of treatment should be determined by the severity of the indication or clinical response. The following general recommendations are made: (See Table 7.)

Click on icon to see table/diagram/image

The recommended duration of therapy for the indication being treated should not be exceeded.
Moxifloxacin 400 mg film-coated tablets and moxifloxacin 400 mg solution for infusion have been studied in clinical trials for up to 21 days (in complicated skin and skin structure infections).
Children and adolescents: Efficacy and safety of Moloxin in children and adolescents have not been established (see Contraindications).
Geriatric patients: No adjustment of dosage is required in elderly.
Ethnic differences: No adjustment of dosage is required in ethnic groups.
Patients with hepatic impairment: No dosage adjustment is required in patients with mild or moderate impaired liver function. The use of moxifloxacin is not recommended in patients with severe hepatic impairment (Child Pugh C) (see Precautions).
Patients with renal impairment: No dose adjustment is required in patients with any degree of renal impairment (including creatinine clearance < 30 mL/min/1.73m²) and in patients on chronic dialysis i.e. hemodialysis and continuous ambulatory peritoneal dialysis.